Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CONTINUOUS-INFUSION INTERLEUKIN-2' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 67 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Kaufman, HL; DeRaffele, G; Divito, J; Horig, H; Lee, D; Panicali, D; Voulo, M
      A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma

      HUMAN GENE THERAPY
    2. Dillman, RO; DeLeon, C; Beutel, LD; Barth, NM; Schwartzberg, LS; Spitler, LE; Garfield, DH; O'Connor, AA; Nayak, SK
      Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    3. Heinzer, H; Huland, E; Huland, H
      Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer

      WORLD JOURNAL OF UROLOGY
    4. Elias, L; Hunt, WC
      A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy

      ONCOLOGY
    5. Ravaud, A
      Cell therapy for solid tumors

      BULLETIN DU CANCER
    6. Dillman, RO; Soori, G; Wiemann, MC; Schulof, R; Dobbs, TW; Ruben, RH; DePriest, CB; Church, C
      Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: Final results of Cancer Biotherapy Research Group94-11

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    7. Dillman, RO; Beutel, LD; Cornforth, AN; Nayak, SK
      Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    8. Fisher, RI; Rosenberg, SA; Fyfe, G
      Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    9. Skubitz, KM; Anderson, PM
      Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial

      ANTI-CANCER DRUGS
    10. Hoffman, DMJ; Gitlitz, BJ; Belldegrun, A; Figlin, RA
      Adoptive cellular therapy

      SEMINARS IN ONCOLOGY
    11. Dillman, RO
      What to do with IL-2?

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    12. Queirolo, P; Ponte, M; Gipponi, M; Cafiero, F; Peressini, A; Semino, C; Pietra, G; Lionetto, R; Vecchio, S; Ribizzi, I; Melioli, G; Sertoli, MR
      Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: A phase III pilot trial

      ANNALS OF SURGICAL ONCOLOGY
    13. Figlin, RA; Thompson, JA; Bukowski, RM; Vogelzang, NJ; Novick, AC; Lange, P; Steinberg, GD; Belldegrun, AS
      Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

      JOURNAL OF CLINICAL ONCOLOGY
    14. MCDERMOTT DF; TREHU EG; MIER JW; SORCE D; RAND W; RONAYNE L; KAPPLER K; CLANCY M; KLEMPNER M; ATKINS MB
      A 2-PART PHASE-I TRIAL OF HIGH-DOSE INTERLEUKIN-2 IN COMBINATION WITHSOLUBLE (CHINESE-HAMSTER OVARY) INTERLEUKIN-1 RECEPTOR

      Clinical cancer research
    15. MCDERMOTT DF; TREHU EG; MIER JW; SORCE D; RAND W; RONAYNE L; KAPPLER K; CLANCY M; KLEMPNER M; ATKINS MB
      A 2-PART PHASE-I TRIAL OF HIGH-DOSE INTERLEUKIN-2 IN COMBINATION WITHSOLUBLE (CHINESE-HAMSTER OVARY) INTERLEUKIN-1 RECEPTOR

      Clinical cancer research
    16. TOURANI JM; PFISTER C; BERDAH JF; BENHAMMOUDA A; SALZE P; MONNIER A; PAULE B; GUILLET P; CHRETIEN Y; BREWER Y; DIPALMA M; UNTEREINER M; MALAURIE E; TADRIST Z; PAVLOVITCH JM; HAUTEVILLE D; MEJEAN A; AZAGURY M; MAYEUR D; LUCAS V; KRAKOWSKI I; LARREGAINFOURNIER D; ABOURACHID H; ANDRIEU JM; CHASTANG C
      OUTPATIENT TREATMENT WITH SUBCUTANEOUS INTERLEUKIN-2 AND INTERFERON-ALPHA ADMINISTRATION IN COMBINATION WITH FLUOROURACIL IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA - RESULTS OF A SEQUENTIAL NONRANDOMIZED-PHASE-II STUDY

      Journal of clinical oncology
    17. ORUCEVIC A; LALA PK
      ROLE OF NITRIC-OXIDE IN IL-2 THERAPY-INDUCED CAPILLARY LEAK SYNDROME

      Cancer metastasis reviews
    18. NEGRIER S; ESCUDIER B; LASSET C; DOUILLARD JY; SAVARY J; CHEVREAU C; RAVAUD A; MERCATELLO A; PENY J; MOUSSEAU M; PHILIP T; TURSZ T
      RECOMBINANT HUMAN INTERLEUKIN-2, RECOMBINANT HUMAN INTERFERON ALPHA-2A, OR BOTH IN METASTATIC RENAL-CELL CARCINOMA

      The New England journal of medicine
    19. NAGLER A; ACKERSTEIN A; BENSHAHAR M; OR R; NAPARSTEK E; BENYOSEF R; SLAVIN S
      CONTINUOUS INTERLEUKIN-2 INFUSION COMBINED WITH CYCLOPHOSPHAMIDE-BASED COMBINATION CHEMOTHERAPY IN THE TREATMENT OF HEMATO-ONCOLOGICAL MALIGNANCIES - RESULTS OF A PHASE I-II STUDY

      Acta haematologica
    20. FISHER RI; ROSENBERG SA; SZNOL M; PARKINSON DR; FYFE G
      HIGH-DOSE ALDESLEUKIN IN RENAL-CELL CARCINOMA - LONG-TERM SURVIVAL UPDATE

      The cancer journal from Scientific American
    21. KRUIT WHJ; GOEY SH; LAMERS CHJ; GRATAMA JW; VISSER B; SCHMITZ PIM; EGGERMONT AMM; BOLHUIS RLH; STOTER G
      HIGH-DOSE REGIMEN OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN COMBINATION WITH LYMPHOKINE-ACTIVATED KILLER-CELLS IN PATIENTS WITH METASTATIC RENAL-CELL-CANCER

      Journal of immunotherapy with emphasis on tumor immunology
    22. MARIA BL; MEDINA CD; HOANG KBN; PHILLIPS MI
      GENE-THERAPY FOR NEUROLOGIC DISEASE - BENCHTOP DISCOVERIES TO BEDSIDEAPPLICATIONS .1. THE BENCH

      Journal of child neurology
    23. KRUIT WHJ; STOTER G
      THE ROLE OF ADOPTIVE IMMUNOTHERAPY IN SOLID CANCERS

      Netherlands journal of medicine
    24. FLAHERTY LE; LIU PY; UNGER J; SONDAK VK
      COMPARISON OF PATIENT CHARACTERISTICS AND OUTCOME BETWEEN A SINGLE-INSTITUTION PHASE-II TRIAL AND A COOPERATIVE-GROUP PHASE-II TRIAL WITH IDENTICAL ELIGIBILITY IN METASTATIC MELANOMA

      American journal of clinical oncology
    25. PHILIP PA; FLAHERTY L
      TREATMENT OF MALIGNANT-MELANOMA WITH INTERLEUKIN-2

      Seminars in oncology
    26. SKEEL RT; QUAN WDY; PALACKDHARRY CS
      COMMON CANCERS - IMMUNOTHERAPY AND MULTIDISCIPLINARY THERAPY .3. IMMUNOTHERAPY FOR CANCER - HARNESSING THE HOST IMMUNE DEFENSES - BIOLOGIC MECHANISMS AND RESULTS IN MELANOMA AND RENAL CELL CARCINOMA .4. MULTIDISCIPLINARY THERAPY OF BREAST, COLORECTAL, AND LUNG CANCER

      Disease-a-month
    27. TOURANI JM; JAILLONABRAHAM C; LUCAS V; CHRETIEN Y; MAYEUR D; DIPALMA M; BOAZIZ C; GRISE P; VARETTE C; PAVLOVITCH JM; LARREGAIN D; ECSTEIN E; UNTEREINER M; ANDRIEU JM
      SUBCUTANEOUS ADMINISTRATION OF INTERLEUKIN-2 IN TREATMENT OF PATIENTSWITH METASTATIC RENAL-CELL CARCINOMA - 3-YEAR RESULTS OF SCAPP-I TRIAL

      Bulletin du cancer
    28. NOBLE S; GOA KL
      ALDESLEUKIN (RECOMBINANT INTERLEUKIN-2) - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES, CLINICAL EFFICACY AND TOLERABILITY IN PATIENTS WITH METASTATIC MELANOMA

      Biodrugs
    29. BEAR HD; HAMAD GG; KOSTUCHENKO PJ
      BIOLOGIC THERAPY OF MELANOMA WITH CYTOKINES AND LYMPHOCYTES

      Seminars in surgical oncology
    30. TOURANI JM; GRISE P; LUCAS V; MAYEUR D; DUFOUR B; DIPALMA M; BOAZIZ C; PAVLOVITCH JM; PUJADELAURAINE E; LARREGAIN D; UNTEREINER M
      INTERLEUKIN-2 IN OUTPATIENTS WITH RENAL-CELL CARCINOMA - SCAPP1 TRIAL

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    31. TREHU EG; MIER JW; DUBOIS JS; SORCE D; KLEMPNER MS; EPSTEIN M; DINARELLO CA; SHAPIRO L; KAPPLER K; RONAYNE L; ATKINS MB
      PHASE-I TRIAL OF INTERLEUKIN-2 IN COMBINATION WITH THE SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR P75 IGG CHIMERA

      Clinical cancer research
    32. CURTI BD; OCHOA AC; URBA WJ; ALVORD WG; KOPP WC; POWERS G; HAWK C; CREEKMORE SP; GAUSE BL; JANIK JE; HOLMLUND JT; KREMERS P; FENTON RG; MILLER L; SZNOL S; SMITH JW; SHARFMAN WH; LONGO DL
      INFLUENCE OF INTERLEUKIN-2 REGIMENS ON CIRCULATING POPULATIONS OF LYMPHOCYTES AFTER ADOPTIVE TRANSFER OF ANTI-CD3-STIMULATED T-CELLS - RESULTS FROM A PHASE-I TRIAL IN CANCER-PATIENTS

      Journal of immunotherapy with emphasis on tumor immunology
    33. CHANG AE; SHU SY
      CURRENT STATUS OF ADOPTIVE IMMUNOTHERAPY OF CANCER

      Critical reviews in oncology/hematology
    34. GOEY SH; VERWEIJ J; STOTER G
      IMMUNOTHERAPY OF METASTATIC RENAL-CELL CANCER

      Annals of oncology
    35. VILLIKKA K; PYRHONEN S
      CYTOKINE THERAPY OF MALIGNANT-MELANOMA

      Annals of medicine
    36. SOKOLOFF MH; DEKERNION JB; FIGLIN RA; BELLDEGRUN A
      CURRENT MANAGEMENT OF RENAL-CELL CARCINOMA

      Ca
    37. KRUIT WHJ; PUNT CJA; GOEY SH; DEMULDER PHM; GRATAMA JW; EGGERMONT AMM; BOLHUIS RLH; STOTER G
      DOSE EFFICACY STUDY OF 2 SCHEDULES OF HIGH-DOSE BOLUS ADMINISTRATION OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN METASTATIC MELANOMA

      British Journal of Cancer
    38. LUITEN RM; CONEY LR; FLEUREN GJ; WARNAAR SO; LITVINOV SV
      GENERATION OF CHIMERIC BISPECIFIC G250 ANTI-CD3 MONOCLONAL-ANTIBODY, A TOOL TO COMBAT RENAL-CELL CARCINOMA/

      British Journal of Cancer
    39. ORUCEVIC A; LALA PK
      N-G-NITRO-L-ARGININE METHYL-ESTER, AN INHIBITOR OF NITRIC-OXIDE SYNTHESIS, AMELIORATES INTERLEUKIN 2-INDUCED CAPILLARY LEAKAGE AND REDUCES TUMOR-GROWTH IN ADENOCARCINOMA-BEARING MICE

      British Journal of Cancer
    40. INOUE H; ARINAGA S; ADACHI M; ASOH T; UEO H; AKIYOSHI T
      IMMUNOHISTOCHEMICAL FEATURES OF HLA-DR ANTIGEN EXPRESSION AND LYMPHOID INFILTRATES IN GASTRIC-CARCINOMA AFTER LOW-DOSE INTERLEUKIN-2 AND MITOMYCIN-C

      Journal of immunotherapy with emphasis on tumor immunology
    41. STADLER WM; VOGELZANG NJ
      LOW-DOSE INTERLEUKIN-2 IN THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA

      Seminars in oncology
    42. PIERCE WC; BELLDEGRUN A; FIGLIN RA
      CELLULAR THERAPY - SCIENTIFIC RATIONALE AND CLINICAL-RESULTS IN THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA

      Seminars in oncology
    43. TANEJA SS; PIERCE W; FIGLIN R; BELLDEGRUN A
      IMMUNOTHERAPY FOR RENAL-CELL CARCINOMA - THE ERA OF INTERLEUKIN-2-BASED TREATMENT

      Urology
    44. LAW TM; MOTZER RJ; MAZUMDAR M; SELL KW; WALTHER PJ; OCONNELL M; KHAN A; VLAMIS V; VOGELZANG NJ; BAJORIN DF
      PHASE-III RANDOMIZED TRIAL OF INTERLEUKIN-2 WITH OR WITHOUT LYMPHOKINE-ACTIVATED KILLER-CELLS IN THE TREATMENT OF PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA

      Cancer
    45. ESCUDIER B; FARACE F; THEODORE C; ANGEVIN E; COURT B; COUANET D; DIETRICH PY; CULINE S; PALLARDY M; HERCEND T; DROZ JP
      A NEW SCHEDULE OF INTERLEUKIN-2 FOR METASTATIC RENAL-CELL CARCINOMA -THE INSTITUT GUSTAVE-ROUSSY STUDY

      Bulletin du cancer
    46. OLEKSOWICZ L; SPARANO J; OBOYLE K; VENKATRAJ U; WIERNIK PH; DUTCHER JP
      INTERLEUKINS IN CANCER-THERAPY - RATIONALE AND CURRENT STATUS

      CLINICAL IMMUNOTHERAPEUTICS
    47. SUSSMAN JJ; SHU S; SONDAK VK; CHANG AE
      ACTIVATION OF T-LYMPHOCYTES FOR THE ADOPTIVE IMMUNOTHERAPY OF CANCER

      Annals of surgical oncology
    48. ESCUDIER B; RAVAUD A; FABBRO M; DOUILLARD JY; NEGRIER S; CHEVREAU C; MIGNOT L; BAUME D; DORVAL T; VIGNAL F; FARACE F; MARANINCHI D
      HIGH-DOSE INTERLEUKIN-2 2 DAYS A WEEK FOR METASTATIC RENAL-CELL CARCINOMA - A FNCLCC MULTICENTER STUDY

      Journal of immunotherapy with emphasis on tumor immunology
    49. DILLMAN RO
      THE CLINICAL-EXPERIENCE WITH INTERLEUKIN-2 IN CANCER-THERAPY

      Cancer biotherapy
    50. BAXEVANIS CN; PAPAMICHAIL M
      CHARACTERIZATION OF THE ANTITUMOR IMMUNE-RESPONSE IN HUMAN CANCERS AND STRATEGIES FOR IMMUNOTHERAPY

      Critical reviews in oncology/hematology
    51. VLASVELD LT; RANKIN EM
      RECOMBINANT INTERLEUKIN-2 IN CANCER - BASIC AND CLINICAL ASPECTS

      Cancer treatment reviews
    52. GOLD JE; OSBAND ME; KRANE RJ
      ADOPTIVE CELLULAR THERAPY OF UROLOGICAL NEOPLASTIC DISEASE

      Cancer treatment reviews
    53. SCHOMBURG A; KIRCHNER H; LOPEZHANNINEN E; MENZEL T; RUDOLPH P; KORFER A; FENNER M; POLIWODA H; ATZPODIEN J
      HEPATIC AND SEROLOGIC TOXICITY OF SYSTEMIC INTERLEUKIN-2 AND OR INTERFERON-ALPHA - EVIDENCE OF A RISK-BENEFIT ADVANTAGE OF SUBCUTANEOUS THERAPY

      American journal of clinical oncology
    54. BRUTON JK; KOELLER JM
      RECOMBINANT INTERLEUKIN-2

      Pharmacotherapy
    55. OPPENHEIM MH; LOTZE MT
      INTERLEUKIN-2 - SOLID-TUMOR THERAPY

      Oncology
    56. JONES M; PHILIP T; PALMER P; VONDERMAASE H; VINKE J; ELSON P; FRANKS CR; SELBY P
      THE IMPACT OF INTERLEUKIN-2 ON SURVIVAL IN RENAL-CANCER - A MULTIVARIATE-ANALYSIS

      Cancer biotherapy
    57. KETLINSKY SA
      CLINICAL-APPLICATION OF RECOMBINANT CYTOK INES - PROSPECTS

      VESTNIK ROSSIISKOI AKADEMII MEDITSINSKIKH NAUK
    58. SPARANO JA; FISHER RI; SUNDERLAND M; MARGOLIN K; ERNEST ML; SZNOL M; ATKINS MB; DUTCHER JP; MICETICH KC; WEISS GR; DOROSHOW JH; ARONSON FR; RUBINSTEIN LV; MIER JW
      RANDOMIZED PHASE-III TRIAL OF TREATMENT WITH HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON ALFA-2A IN PATIENTS WITH ADVANCED MELANOMA

      Journal of clinical oncology
    59. MANSECK A; WIRTH M
      IMMUNE THERAPY OF ADVANCED RENAL-CELL CAR CINOMA

      Der Urologe
    60. SCHOMBURG A; KIRCHNER H; ATZPODIEN J
      RENAL, METABOLIC, AND HEMODYNAMIC SIDE-EFFECTS OF INTERLEUKIN-2 AND OR INTERFERON-ALPHA - EVIDENCE OF A RISK-BENEFIT ADVANTAGE OF SUBCUTANEOUS THERAPY

      Journal of cancer research and clinical oncology
    61. BUTER J; SLEIJFER DT; VANDERGRAAF WTA; DEVRIES EGE; WILLEMSE PHB; MULDER NH
      A PROGRESS REPORT ON THE OUTPATIENT TREATMENT OF PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA USING SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2

      Seminars in oncology
    62. THOMPSON JA; BENYUNES MC; BIANCO JA; FEFER A
      TREATMENT WITH PENTOXIFYLLINE AND CIPROFLOXACIN REDUCES THE TOXICITY OF HIGH-DOSE INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS

      Seminars in oncology
    63. WALTHER MM; ALEXANDER RB; WEISS GH; VENZON D; BERMAN A; PASS HI; LINEHAN WM; ROSENBERG SA
      CYTOREDUCTIVE SURGERY PRIOR TO INTERLEUKIN-2-BASED THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA

      Urology
    64. LALA PK; PARHAR RS
      ERADICATION OF SPONTANEOUS AND EXPERIMENTAL ADENOCARCINOMA METASTASESWITH CHRONIC INDOMETHACIN AND INTERMITTENT IL-2 THERAPY

      International journal of cancer
    65. WHITTINGTON R; FAULDS D
      INTERLEUKIN-2 - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN PATIENTS WITH CANCER

      Drugs
    66. CHANG AE; GEIGER JD; SONDAK VK; SHU SY
      ADOPTIVE CELLULAR THERAPY OF MALIGNANCY

      Archives of surgery
    67. SCHOMBURG A; KIRCHNER H; ATZPODIEN J
      HEMATOTOXICITY OF INTERLEUKIN-2 IN MAN - CLINICAL EFFECTS AND COMPARISON OF VARIOUS TREATMENT REGIMENS

      Acta haematologica


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/10/20 alle ore 09:17:42